Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408660 | 0.88 | PSMD14 (0.32) | L3MBTL1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL6336269 | 0.85 | SMN1; SMN2 (0.39) | L3MBTL1KMT2AALDH1A1TDP1 | |
| SCHEMBL6407647 | 0.78 | PI4KB (0.34) | L3MBTL1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL6407500 | 0.73 | L3MBTL1 (0.41) | L3MBTL1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL6336973 | 0.72 | CDK2 (0.41) | L3MBTL1KMT2AKDM4E | |
| SCHEMBL6405533 | 0.69 | PKM (0.37) | L3MBTL1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6405526 | 0.69 | PKM (0.37) | L3MBTL1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6503511 | 0.68 | HPGD (0.40) | L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL6410153 | 0.66 | KDM4E (0.43) | L3MBTL1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL6408653 | 0.66 | PI4KB (0.40) | L3MBTL1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| US-6969713-B2 | Piperidine and piperazine acetamide derivatives | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| EP-1242427-B1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-08-13 | — | — | EP | disclosed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | CYP3A5, IL5, ABCC5 | L3MBTL1 4884/4885KMT2A 2331/4885KDM4E 1104/4885 |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | IL5, VIP, EP300 | L3MBTL1 4881/4885KMT2A 2632/4885KDM4E 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.